These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19734450)

  • 1. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
    Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
    Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776.
    Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X
    Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
    Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
    Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1.
    Xie J; Bai J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S355-62. PubMed ID: 24290221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
    Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
    Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
    Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
    Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.
    Chen LS; Balakrishnan K; Gandhi V
    Biochem Pharmacol; 2010 Dec; 80(12):1936-45. PubMed ID: 20696142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
    Chen R; Guo L; Chen Y; Jiang Y; Wierda WG; Plunkett W
    Blood; 2011 Jan; 117(1):156-64. PubMed ID: 20971952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
    Chen R; Keating MJ; Gandhi V; Plunkett W
    Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
    Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.